Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Immuno-Oncology Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for ILDR2 drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | ILDR2 ECD-Fc Recombinant Protein High purity (>95%), Endotoxin <1.0 EU/μg. Sequence Verified. HEK293 expressed for native glycosylation. |
View ILDR2 Products |
| Gene Delivery | ILDR2 Promise-ORF / Lentivirus Full-length human ILDR2 ORF for stable cell line construction and flow cytometry validation. |
View ILDR2 Products |
| Benchmark Ab | Anti-ILDR2 Recombinant Antibody Recombinant positive control derived from clinical benchmark sequence (BAY 1905254 biosimilar). |
View ILDR2 Products |
| Validator | ILDR2 siRNA Set Target-specific knockdown pool for functional specificity verification in primary cells. |
View ILDR2 Products |
| Related Target A | LSR (Lipolysis-stimulated lipoprotein receptor) High-homology family member. Crucial for off-target counter-screening to ensure safety. |
View LSR Products |
| Related Target B | ILDR1 (Immunoglobulin-like domain-containing receptor 1) Subfamily homolog. Required for specificity profiling of lead candidate antibodies. |
View ILDR1 Products |
| Related Target C | PD-L1 (CD274) Synergistic immune checkpoint. Often evaluated in combination with ILDR2 blockade. |
View PD-L1 Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Subfamily cross-reactivity (LSR / ILDR1) | Homolog panel proteins (LSR, ILDR1) strictly verified by mass spectrometry and SDS-PAGE |
| Species cross-reactivity evaluation | Human, Mouse, and Cynomolgus ILDR2 ortholog proteins available with >95% purity |
| Lack of functional screening controls | Clinical Benchmark Antibodies (BAY 1905254 biosimilar) included for assay calibration |
| False positives in binding assays | Sequence-verified proteins with controlled endotoxin levels to prevent non-specific immune activation |
Live ILDR2 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for ILDR2 therapeutics is intensifying, with major players shifting focus from traditional monoclonals to combination regimens. As first-generation therapies reach clinical evaluation, the next wave of R&D is targeting the tumor microenvironment (TME) by combining ILDR2 blockade with established checkpoint inhibitors. ILDR2, primarily expressed on tumor-associated macrophages (TAMs) and tumor cells, serves as a novel myeloid-associated checkpoint, making it a prime candidate for overcoming resistance to anti-PD-1/PD-L1 therapies.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Monoclonal Antibody (mAb) | Bayer, Compugen | Advanced Solid Tumors, Colorectal Cancer | Epitope mapping & species cross-reactivity (Need high-purity ECD-Fc proteins) |
| Combination Therapy | Clinical Investigators | PD-1 Resistant Tumors | Synergy validation assays (Need PD-L1 and ILDR2 benchmark antibodies) |
| Myeloid-Targeting Agents | Biotech Startups | Immunosuppressive TME | Macrophage polarization assays (Need stable ILDR2 lentivirus for cell lines) |